(openPR) - Nadrich & Cohen, LLP reports that the U.S. Food and Drug Administration has issued an updated safety warning for the heart medication Multaq.

Los Angeles, CA, January 24, 2012 – The U.S. Food and Drug Administration has issued an updated safety communication advising patients who use the heart medication Multaq (dronedarone) of the potential for serious complications.

The updated safety communication was issued on December 19, 2011 after an FDA safety review determined that the drug increased the risk of serious cardiovascular events, including death, when used by patients to treat a heart rhythm condition known as permanent atrial fibrillation (AF).

According to the FDA website, the safety review was based on data drawn from two clinical trials, the PALLAS trial (Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy) and the ATHENA trial, which supported the approval of Multaq for use among patients with non-permanent atrial fibrillation.

The FDA announced that it would require updated warning labels for Multaq advising health care professionals not to give the drug to patients with AF who cannot or will not be converted to permanent AF because it could double the risk heart attack or stroke. The move has many cardiovascular experts closely monitoring the future of the drug.

Multaq was first approved by the FDA in July 2009. Through October 2011, approximately 1.3 million prescriptions were filled for the drug with another 278,000 patients purchasing the drug through outpatient retail pharmacies in the U.S.

Patients who experienced a heart attack, stroke or other complications after taking Multaq are urged to complete a MedWatch form by visiting the Food and Drug Administration’s website. It is also recommended that you contact an experienced persona injury lawyer to discuss your rights.

Nadrich & Cohen LLP offers confidential, no-cost consultations to Multaq users who believe they were harmed by the drug. Help is available by calling the firm’s injury hotline at 1-800-722-0765 or by completing an online case evaluation form at www.personalinjurylawcal.com.

Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California. The firm specializes in handling mass tort actions and representing individuals in cases involving pharmaceutical companies, medical device makers and other product manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.

In addition to handling Multaq side effects claims, Nadrich & Cohen, LLP investigates cases involving Accutane, Avandia, DePuy Hip Implants, Zimmer Hips, Wright Conserve Hips, Vaginal Mesh, Pradaxa, Stevens-Johnson Syndrome, Reflex Sympathy Dystrophy, Fen Phen and PPH, Depakote and Reglan. All cases are accepted on a contingency basis, meaning there is never a fee unless we recover a judgment on your behalf.

The time you have to file an injury claim is limited, so it’s important to act as quickly as possible to protect your rights. Call 1-800-722-0765 today to speak with a qualified personal injury expert or visit www.personalinjurylawcal.com.

Nadrich & Cohen LLP is a national law firm specializing in representing individuals who have been injured by defective medical devices, harmful prescription drugs, faulty products, car accidents, motorcycle accidents and dog bites. For more information, visit www.personalinjurylawcal.com.

Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com